Discovery and biological evaluation of some (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivatives containing an anthraquinone moiety as potent xanthine oxidase inhibitors
A series of (1H-1,2,3-triazol-4-yl)methoxybenzaldehyde derivativescontaining an anthraquinone moiety were synthesized and identified as novel xanthine oxidase inhibitors. Among them, the most promising compounds 1h and 1k were obtained with IC50 values of 0.6 μM and 0.8 μM, respectively, which were more than 10-fold potent compared with allopurinol. The Lineweaver-Burk plot revealed that compound
合成了一系列含有蒽醌部分的(1 H -1,2,3-三唑-4-基)甲氧基苯甲醛衍生物,并将其鉴定为新型黄嘌呤氧化酶抑制剂。其中,获得最有前途的化合物1h和1k的IC 50值分别为0.6μM和0.8μM,与别嘌呤醇相比,具有50倍以上的效力。Lineweaver-Burk图显示化合物1h充当了混合型黄嘌呤氧化酶抑制剂。SAR分析表明,对于抑制效力,苯甲醛部分比蒽醌部分起着更重要的作用。黄嘌呤氧化酶被1h显着抑制的基础 通过分子模型研究合理化。
Discovery of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives as novel xanthine oxidase inhibitors
A series of 4-(phenoxymethyl)-1H-1,2,3-triazole derivatives were designed, synthesized, and evaluated for their xanthine oxidase (XO) inhibitory activities. Among these compounds, 9m emerged as the most effective XO inhibitor with an IC50 value of 0.70 μM, which was approximately 14-fold more potent than allopurinol. Additionally, compound 9m displayed favorable drug-like properties with ligand efficiency
设计、合成了一系列 4-(苯氧基甲基)-1 H -1,2,3-三唑衍生物,并评估了它们的黄嘌呤氧化酶 (XO) 抑制活性。在这些化合物中,9m成为最有效的 XO 抑制剂,其 IC 50值为 0.70 μM,比别嘌呤醇强约 14 倍。此外,化合物9m表现出良好的药物样特性,配体效率 (LE) 和亲脂性配体效率 (LLE) 值分别为 0.33 和 3.41。我们通过分子对接和分子动力学研究进一步探索了9m与XO复合物的结合模式。体内降尿酸研究也表明9m能有效降低大鼠血清尿酸水平。总之,化合物9m可能是进一步开发 XO 抑制剂的有希望的先导。
topoisomerase activity is one of the well-known focuses in cancer chemotherapy. Here, we describe the design and synthesis of a novel series of pyrazolo[4,3-f]quinolines with potential anticancer/topoisomerase inhibition activity. Forty newly designed pyrazolo[4,3-f]quinoline derivatives were synthesized via inverse imino Diels–Alder reaction. The antiproliferative activity of the synthesized derivatives was
随着癌症治疗的几个目标,DNA拓扑异构酶活性的抑制是癌症化疗中众所周知的焦点之一。在这里,我们描述了具有潜在抗癌/拓扑异构酶抑制活性的新型吡唑并[4,3- f ]喹啉系列的设计和合成。通过反亚氨基Diels-Alder反应合成了40种新设计的吡唑并[4,3 - f ]喹啉衍生物。最初在人 NUGC-3 癌细胞系中测量了合成衍生物的抗增殖活性。然后,选择的化合物1B、1C、1M、2A、2D、2E、2F和2R在被测化合物中具有较高活性的化合物针对 ACHN、HCT-15、MM231、NCI-H23、NUGC-3 和 PC-3 等六种癌细胞系进行了筛选。结果表明,化合物1M、2E和2P在所有 GI 50低于 8 µM的癌细胞系中最有效。其中,2E在 100 µM 剂量下显示出与依托泊苷(阳性对照)等效的拓扑异构酶 IIα 活性抑制模式。